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The study was set up to review the current susceptibility patterns of Salmonella isolates to 
quinolones. A systematic literature search on in vitro and in vivo susceptibility patterns of 
Salmonella isolates to various quinolones was carried out from relevant published articles over 
a 25 year interval (1982-2007). Data obtained was analysed using simple descriptive methods. 
Susceptibility patterns of 55,853 Salmonella isolates to quinolones from 845 reports were 
reviewed. The most active quinolones encountered were (where n= number of Salmonella 
isolates tested): ciprofloxacin, 99%(n=15,432); grepafloxacin, 99%(n=2,701); gemifloxacin, 
97%(n=1,209); ofloxacin, 96%(n=8,692); and sparofloxacin, 93%(n=557). This was followed 
by: enoxacin, 92%(n=2,653); gatifloxacin, 90%(n=788); lomefloxacin, 83%(n=1,823); and 
levofloxacin, 81%(n=3,228). And the least active quinolones against Salmonella spp. were 
norfloxacin, 76%(n=1,355); pefloxacin, 62%(n=4,307); and nalidixic acid, 61%(n=17,542).  
Quinolones at present have been found to be quite effective in the management of enteric 
fever and their use should be sustained. However, susceptibility patterns of the local 
Salmonella isolates should be conducted to identify the most appropriate quinolone to use in 
this environment. Furthermore, in the absence of a susceptibility report, ciprofloxacin, 
grepafloxacin, gemifloxacin, ofloxacin, and sparofloxacin may be considered preferred choices 
on proven diagnosis of enteric fever. 
 




Quinolones are synthetic analogs of nalidixic 
acid and act by inhibiting bacterial DNA 
synthesis by blocking the enzyme DNA 
gyrase. They are presently grouped into four 
generations which include members such as, 
nalidixic acid, lomefloxacin, clinafloxacin and 
moxifloxacin as examples of first, second, 
third, and fourth generations respectively.    
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Among the antimicrobials presently 
available for the treatment of enteric fever, 
preferences for quinolones among clinicians 
appear to be on a steady increase. About 16 
million cases of enteric fever are reported 
globally with over 600,000 deaths yearly 
(Karinki, et al, 2004). Over 75% of the cases 
occur in sub-Saharan Africa, South east 
Asia, the Mediterranean, and parts of central 
and south America (Meltzer, et al, 2005; and 
Ekdahi, et al, 2005).  
There have been varying reports on 
the susceptibility patterns of Salmonella 
isolates to various quinolones globally. 
Findings from Lagos, Nigeria, showed a 
100% activity of both ciprofloxacin and 
ofloxacin and 60% nalidixic acid against 
Salmonella spp. tested (Akinyemi, et al, 
2000). In Kumba, Cameroun, on the other 
hand, treatment failure from ciprofloxacin 
was recorded (Nkemngu, et al, 2005), while 
in Cairo, Egypt, a high nalidixic acid activity 
(over 90%) was recorded (Wasfy, et al, 
1996); however, in India and Pakistan, 
resistance of Salmonella spp. to nalidixic 
acid, ciprofloxacin and other quinolones was 
found to be on the increase (Chandel, and 
Chaudhry, 2001). 
Multidrug resistant Salmonella typhi 
(MDRST) has been on a steady increase 
over the past two decades and has since 
assumed a global dimension (Mermin, et al, 
1998; and Caumes, et al, 2001). This is 
reported to have began with the emergence 
of resistance to chloramphenicol in the late 
1980s after serving for over 40 years as the 
drug of choice (Rowe, et al, 1997; and 
Shanehan, et al, 1998). In Srinagar-Kashmir, 
India a very rare strain of S. typhi phage 
biotype II untypeable (UVS2) was recovered 
from an outbreak of enteric fever and was 
resistant to all the antimicrobial agents 
tested except norfloxacin (Kamili, et al, 
1993). Also in Moscow, Russia, in an 
epidemiological survey, no single 
antimicrobial agent was found to have 
absolute (100%) activity against the 
Salmonella isolates tested (Makhnev, 2003). 
Similarly, in Lagos, Nigeria, 25 of 41(61%) 
isolates of Salmonella spp. from cases of 
pyrexia of unknown origin (PUO) were found 
to be resistant to all the antimicrobials tested 
(Akinyemi, et al, 2005). In like manner, a 
laboratory-based surveillance of Salmonella 
serotype typhi infections in the United States 
showed that 74(24%) were resistant to 1 or 
more antimicrobial agents, while 51(17%) 
were resistant to 5 or more agents, including 
ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole (MDRST) 
(Ackers, et al, 2000).  
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With the proper treatment of enteric 
fever progressively becoming a serious 
challenge among health personnel due to 
the increasing and widespread resistance of 
the organisms to the common drugs (Mirza, 
et al, 2000; Rahman, et al, 2002; Price, et al, 
2001; and Arad, et al, 1996); and with the 
varying reports on the susceptibility patterns 
of Salmonella spp. to various quinolones 
across the globe, a general review of the 
usefulness of this group of drugs in the 
treatment of enteric fevers becomes a 
worthwhile venture.  
Furthermore, in the present scenario 
where Salmonellae appear to be winning the 
antimicrobial war (Nkemngu, et al, 2005; 
Chandel, et al, 2001; and Ackers, et al, 
2000), a periodic review of its antibacterial 
activity becomes necessary. Such 
information would be a veritable tool for 
clinicians who, either for time constraint or 
for lack of adequate facilities may not afford 
to rely on a comprehensive susceptibility 
report prior to commencement of treatment. 
 
MATERIALS AND METHODS 
 
A systematic literature search on 
antimicrobial susceptibility pattern of 
Salmonella species to quinolones was 
undertaken on published articles for a 25 
year interval (1982-2007). This consists of 
articles on in vitro antimicrobial susceptibility 
pattern of individual isolates of Salmonella 
typhi and Salmonella paratyphi to quinolones 
in various research centres across the globe. 
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Data compiled was comprised of relevant 
reports from original articles, review articles, 
short communications and letters to the 
editors. The In vitro susceptibility results 
were standardized by collating findings from 
studies whose methodologies were based on 
the diffusion and dilution methods of National 
Committee for Clinical Laboratory Standards 
(NCCLS) protocol. Similarly, monotherapy 
results from In vivo susceptibilities whose 
interpretations were based on both the 
bacteriological and clinical outcomes of the 
patients were compiled. Data obtained were 





The antimicrobial susceptibility pattern of 
55,853 strains of Salmonella spp. from 845 
reports were reviewed with varying number 
of isolates tested per specific quinolone.  
Salmonella spp. on the average were found 
to be most susceptible to (where n= number 
of Salmonella isolates tested) ciprofloxacin, 
99% (n=15,432); grepafloxacin, 99% 
(n=2,701); gemifloxacin, 97% (n=1,219); 
ofloxacin, 96% (n=8,692); and sparofloxacin, 
93% (n=557). This was followed by 
enoxacin, 92% (n=2,653); gatifloxacin, 90% 
(n=788); lomefloxacin, 83% (n=1,823); and 
levofloxacin, 81% (n=3,228). The least 
sensitive quinolones against Salmonella spp. 
were found to be norfloxacin, 77% 
(n=7,277); moxifloxican, 76% (n=1,355); 
pefloxacin, 62% (n=4,303); and nalidixic 
acid, 61% (n=17,542)  
 
Fig. 1: Susceptibility patterns of 55,853 strains of Salmonella species to quinolone from 845 reports (n= number 




Ciprofloxacin, grepafloxacin, gemifloxacin, 
ofloxacin, and sparofloxacin were on the 
average found to be 99%, 99%, 97%, 96%,  
and 93% active respectively against the 
55,853 Salmonella spp. reviewed. This 
varies from the 23.5% ciprofloxacin 
resistance recorded in Thailand on 1,210 
Salmonella isolates (Hakanen, et al, 2001), 
to the 99.5% susceptibility to ciprofloxacin, 
ofloxacin and gemifloxacin recorded in 
Beijing, China (Jiang, et al, 1997), and the 
100% sensitivity recorded in Port Harcourt, 
Nigeria (Ibe, and Wariso, 1996) and Vienna, 
Austria (Graninger, et al, 1996). In 
Saskatoon, Canada, the activity of 
gemifloxacin against Salmonella spp. and 
other Enterobacteriaceae was found to be 
enhanced over that of ciprofloxacin whose 
activity was significantly higher than that of 
chloramphenicol, cotrimoxazole, ampicillin, 
gentamicin and several cephalosporins 
(Bloneau, et al, 2003). In Japan, Salmonella 
spp. were found to be over 98% susceptible 
to sparofloxacin (Ohnishi, et al, 2000). 
The 56.6% chloramphenicol, 70% 
ampicillin, 50.0% amikacin, 43.3% 
gentamicin, and 40.0% ampicillin resistance 
of Salmonella spp. as against 0% to 
ciprofloxacin and ofloxacin as recorded in 
Rajasthan further proves the therapeutic 
edge quinolones have over these antityphoid 
drugs (Maheshwari, and Agarwal, 1996). In 
Germany, grepafloxacin was found to have 
similar antityphoid properties with 
ciprofloxacin which was in it self over 97% 
active (Dalhoff, and Schmitz, 2003).  
The activities of lomefloxacin, 
levofloxacin, gatifloxacin and enoxacin were 
on the average moderate among the 
Salmonella spp. reviewed (81%-92%). In 
Tokyo, Japan, the activity of levofloxacin and 
a newer quinolone, DK-507K against 
Salmonella and other Enterobacteriaceae 
were found to be high and comparable to 
that of ciprofloxacin, while DK-507K was 
highly active against ciprofloxacin resistant 
strains (Otani, et al, 2003). A large scale 
multi-centre clinical trial of DK-507K may be  
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required to establish its suitability in view of 
its pharmacodynamic advantages over 
ciprofloxacin in the treatment of enteric 
fevers.  
In France, in a study on 2,819 
bacterial strains lomefloxacin and pefloxacin 
were found to have similar activity to 
ciprofloxacin (Soussy, et al, 1990). They 
however showed expanded activity against 
organisms such as Staphylococci, 
Clostridium perfringens, Bacteroides fragilis 
and Branhamella. Also in New Zealand, 
lomefloxacin, besides having high 
antimicrobial properties comparable to 
ciprofloxacin, it was found that, it can 
conveniently be taken once a day with the 
same therapeutic outcome, thus enhancing 
compliance (Wadworth, et al, 1991). In 
Poland, the activity of enoxacin against 362 
clinical bacterial isolates was found to be 
about half that of ciprofloxacin but several 
folds higher than that of the penicillins and 
many second and third generation 
cephalosporins used in typhoid treatment 
(Reeves, et al, 1984). 
The activity profile of norfloxacin, 
moxifloxacin, pefloxacin, and nalidixic acid 
were on the average comparatively lower 
(61%-77%). These drugs on individual basis 
have still been found to be up to four times 
more active than drugs such as amoxicillin, 
ampicillin, chloramphenicol, cotrimoxazole 
and gentamicin, drugs commonly used in the 
treatment of typhoid fevers (Caumes, et al, 
2001; Rowe, et al, 1997; Shanehan, et al, 
1998; and Kamili, et al, 1993). The over 96% 
norfloxacin activity recorded in New York, 
USA (Cunha, et al, 1997); and the over 90% 
In vivo activity of moxifloxacin, getofloxacin 
and grepafloxacin in Germany (Lubasch, et 
al, 2000); and the 21.6% and 12.1% 
resistance of two different strains of 
Salmonellae against nalidixic acid in Seoul, 
South Korea (Choi, et al, 2005), further 
illustrate the widespread regional and 
geographic distribution of the resistance 
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patterns of Salmonella spp. globally. 
Quinolones, though generally active against 
Salmonella spp., activity patterns of 
individual drugs on local isolates should be 
known to aid efficient patient management.  
 
The sub-therapeutic bioavailability 
commonly associated with administration of 
nalidixic acid renders it ineffective in the 
treatment of enteric fevers. Its usefulness in 
predicting the susceptibility pattern of 
Salmonella spp. to other quinolones has well 
been documented in studies from 
Rawalpondi, and Karachi, Pakistan (Anjum, 
et al, 2004; and Zafar, et al, 2005), Tuku, 
Finland (Ray, et al, 2006) and Chandigah, 
India (Hakanen, et al, 1999). This 
susceptibility indicator would aid in timely 
prescription of newer quinolones, especially 
in the developing countries where facilities 
for susceptibility testing of the new drugs 
may be lacking. 
The antityphoid properties of other 
quinolones such as temafloxacin, 
tosufloxacin, sitafloxacin and trovafloxacin 
also need to be ascertained so as to 
establish their usefulness in the treatment of 
enteric fever. 
In conclusion, this study has shown 
that, quinolones are at present considerably 
effective in the treatment of enteric fevers 
and their use should be sustained. They 
could also be a solution to the present rise in 
multidrug resistant Salmonellae (MDRS). 
Their choice should however be based on 
the antimicrobial susceptibility pattern of the 
local Salmonella strains so as to enhance 
efficient enteric fever therapy. Generally, 
ciprofloxacin, grepafloxacin, gemifloxacin, 
ofloxacin and Sparofloxacin may be 
considered on diagnosis of enteric fever in 
the absence of a reliable susceptibility 
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